Skip to main content

Table 1 Baseline characteristics and response-status in RTX treated RA patients.

From: The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

 

Test cohort

(n = 14)

Validation cohort

(n = 26)

Total group

(n = 40)

Demographics

   

Age, years

55 ± 10

59 ± 11

58 ± 11

Female, %

86

85

85

Disease characteristics

   

RA duration, years

11 (5 to 21)

6 (2 to 16)

8 (3 to 17)

DAS28-score

5.7 ± 1.0

5.8 ± 1.2

5.8 ± 1.2

ESR, mm/hr

14 (9 to 31)

29 (13 to 50)

23 (12 to 42)

CRP, mg/L

9 (3 to 19)

14 (6 to 27)

12 (4 to 25)

IgM RF positive, %

71

63

68

ACPA positive, %

79

70

73

Erosive diseases, %

93

59

72

Medication

   

Previous biologicals, n

2 (1 - 2)

2 (1 - 2)

2 (1 - 2)

> 1 Biological in history, %

50

50

50

Previous DMARDS, n

4 (4 - 5)

3 (3 - 4)

4 (3 - 4)

Current prednisolone use, %

93

63

70

Prednisolone dosage, mg/day

9 (7 - 13)

5 (0 - 10)

8 (0 - 10)

Current DMARD use, %

93

77

83

Current statin use, %

21

13

18

Response

   

ΔDAS28

-1.6 (-2.7 - -0.5)

-1.0 (-1.5 - 0.2)

-1.0 (-2.0 - 0.3)

ΔDAS28 > 1.2, %

EULAR responders, %

57

64

65

50

63

55

  1. Continuous variables are presented as mean with standard deviation or median with interquartile range where appropriate. ACPA, anti-cyclic citrullinated protein; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; MTX, methotrexate; RF, rheumatoid factor; SSZ, sulphasalazyne;